Orexigen Therapeutics (OREX), maker of the weightloss drug candidate Contrave, are awaiting FDA approval for the third newest diet pill likely to be approved. Contrave is the third prescription diet drug candidate to face the FDA’s advisory panel this year, and after Vivus’s (VVUS) Qnexa and Arena Pharmaceuticals’s (ARNA) Lorcaserin had their FDA decision delayed due to safety concerns. Currently… Read more →
WASHINGTON DC, USA — The Food and Drug Administration has approved Arena Pharmaceutical’s diet pill Belviq, the first new diet prescription drug for long-term weight loss to enter the U.S. market in over a decade. Despite only achieving modest weight loss in clinical studies, the drug appeared safe enough to win the FDA’s endorsement, amid calls from doctors for new… Read more →
WASHINGTON DC, USA – The Food and Drug Administration on approves a new weight loss drug from Vivus Inc. called Qsymia , that many doctors consider a potential effective therapy in a new generation of anti-obesity pills designed to help patients safely shed pounds. The agency cleared the diet pill Qsymia for adults who are obese or overweight and have… Read more →
Recent Comments